(Q41497390)

English

Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study

scientific article published on 4 February 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 October 2017

Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study (English)

1 reference

Europe PubMed Central

1 October 2017

multicenter clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

Hepatitis C virus

1 reference

based on heuristic

inferred from title

Evguenia Svarovskaia

10

object named as

Evguenia Svarovskaia

0 references

2

object named as

Chloe Orkin

1 reference

Europe PubMed Central

1 October 2017

Jürgen Rockstroh

15

object named as

Jürgen K Rockstroh

1 reference

Europe PubMed Central

1 October 2017

Jean-Michel Molina

1

object named as

Jean-Michel Molina

1 reference

Europe PubMed Central

1 October 2017

author name string

David M Iser

3

1 reference

Europe PubMed Central

1 October 2017

Francisco-Xavier Zamora

4

1 reference

Europe PubMed Central

1 October 2017

Mark Nelson

5

1 reference

Europe PubMed Central

1 October 2017

Christoph Stephan

6

1 reference

Europe PubMed Central

1 October 2017

Benedetta Massetto

7

1 reference

Europe PubMed Central

1 October 2017

Anuj Gaggar

8

1 reference

Europe PubMed Central

1 October 2017

Liyun Ni

9

1 reference

Europe PubMed Central

1 October 2017

Evguenia Svarovskaia

10

1 reference

Europe PubMed Central

1 October 2017

Diana Brainard

11

1 reference

Europe PubMed Central

1 October 2017

G Mani Subramanian

12

1 reference

Europe PubMed Central

1 October 2017

John G McHutchison

13

1 reference

Europe PubMed Central

1 October 2017

Massimo Puoti

14

1 reference

Europe PubMed Central

1 October 2017

PHOTON-2 study team

16

1 reference

Europe PubMed Central

1 October 2017

language of work or name

0 references

publication date

4 February 2015

1 reference

Europe PubMed Central

1 October 2017

1 reference

Europe PubMed Central

1 October 2017

385

1 reference

Europe PubMed Central

1 October 2017

9973

1 reference

Europe PubMed Central

1 October 2017

1098-1106

1 reference

Europe PubMed Central

1 October 2017

Managing HIV/hepatitis C co-infection in the era of direct acting antivirals

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962483-1

7 January 2021

based on heuristic

inferred from DOI database lookup

HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962483-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962483-1

7 January 2021

based on heuristic

inferred from DOI database lookup

HCV and HIV co-infection: mechanisms and management.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962483-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962483-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962483-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962483-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Sofosbuvir for previously untreated chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962483-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962483-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962483-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962483-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962483-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Sofosbuvir for chronic hepatitis C virus infection genotype 1-4 in patients coinfected with HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962483-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962483-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962483-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962483-1

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962483-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962483-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(14)62483-1

1 reference

Europe PubMed Central

1 October 2017

1 reference

Europe PubMed Central

1 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41497390&oldid=1922441297"